Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke - The Systolic Hypertension in the Elderly Program (SHEP)

被引:214
作者
Perry, HM
Davis, BR
Price, TR
Applegate, WB
Fields, WS
Guralnik, JM
Kuller, L
Pressel, S
Stamler, J
Probstfield, JL
机构
[1] Washington Univ, Dept Med, St Louis, MO 63110 USA
[2] Univ Texas, Hlth Sci Ctr, Sch Publ Hlth, Houston, TX USA
[3] Univ Maryland, Sch Med, Dept Neurol, Baltimore, MD 21201 USA
[4] Wake Forest Univ, Dept Med, Winston Salem, NC 27109 USA
[5] NIA, Bethesda, MD 20892 USA
[6] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA
[7] Northwestern Univ, Sch Med, Dept Prevent Med, Chicago, IL USA
[8] Univ Washington, Dept Med, Seattle, WA USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2000年 / 284卷 / 04期
关键词
D O I
10.1001/jama.284.4.465
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context The Systolic Hypertension in the Elderly Program (SHEP) demonstrated that treating isolated systolic hypertension in older patients decreased incidence of total stroke, but whether all types of stroke were reduced was not evaluated. Objective To investigate antihypertensive drug treatment effects on incidence of stroke by type and subtype, timing of strokes, case-fatality rates, stroke residual effects, and relationship of attained systolic blood pressure to stroke incidence. Design The SHEP study, a randomized, double-blind, placebo-controlled trial began March 1, 1985, and had an average follow-up of 4.5 years. Setting and Participants A total of 4736 men and women aged 60 years or older with isolated systolic hypertension at 16 clinical centers in the United States. Interventions Patients were randomly assigned to receive treatment with 12.5 mg/d of chlorthalidone (step 1); either 25 mg/d of atenolol or 0.05 mg/d of reserpine (step 2) could be added (n = 2365); or placebo (n = 2371). Main Outcome Measures Occurrence, type and subtype, and timing of first strokes and stroke fatalities; and change in stroke incidence for participants (whether in active treatment or placebo groups) reaching study-specific systolic blood pressure goal (decrease of at least 20 mm Hg from baseline to below 160 mm Hg) compared with participants not reaching goal. Results A total of 85 and 132 participants in the active treatment and placebo groups, respectively, had ischemic strokes (adjusted relative risk [RR], 0.63; 95% confidence interval [CI], 0.48-0.82); 9 and 19 had hemorrhagic strokes (adjusted RR, 0.46; 95% CI, 0.21-1.02); and 9 and 8 had strokes of unknown type (adjusted RR, 1.05; 95% CI, 0.40-2.73), respectively. Four subtypes of ischemic stroke were observed in active treatment and placebo group participants, respectively, as follows: for lacunar, n=23 and n=43 (adjusted RR, 0.53; 95% CI, 0.32-0.88); for embolic, n=9 and n=16 (adjusted RR, 0.56; 95% CI, 0.25-1.27); for atherosclerotic, n=13 and n=13 (adjusted RR, 0.99; 95% CI, 0.46-2.15); and for unknown subtype, n=40 and n=60 (adjusted RR, 0.64; 95% CI, 0.43-0.96). Treatment effect was observed within 1 year for hemorrhagic strokes but was not seen until the second year for ischemic strokes. Stroke incidence significantly decreased in participants attaining study-specific systolic blood pressure goals. Conclusions In this study, antihypertensive drug treatment reduced the incidence of both hemorrhagic and ischemic (including lacunar) strokes. Reduction in stroke incidence occurred when specific systolic blood pressure goals were attained.
引用
收藏
页码:465 / 471
页数:7
相关论文
共 21 条
  • [1] ANIM JI, 1989, E AFR MED J, V66, P468
  • [2] [Anonymous], 1991, JAMA, V265, P3255
  • [3] HYPERTENSION AND CEREBRAL ATHEROSCLEROSIS
    BAKER, AB
    RESCH, JA
    LOEWENSON, RB
    [J]. CIRCULATION, 1969, 39 (05) : 701 - +
  • [4] RATIONALE AND DESIGN
    BORHANI, NO
    APPLEGATE, WB
    CUTLER, JA
    DAVIS, BR
    FURBERG, CD
    LAKATOS, E
    PAGE, L
    PERRY, HM
    SMITH, WM
    PROBSTFIELD, JL
    [J]. HYPERTENSION, 1991, 17 (03) : 2 - 15
  • [5] COMPARATIVE INCIDENCE OF CEREBROVASCULAR LESIONS IN NORMOTENSIVE AND HYPERTENSIVE PATIENTS
    COLE, FM
    YATES, PO
    PATH, MC
    [J]. NEUROLOGY, 1968, 18 (03) : 255 - +
  • [6] COX DR, 1972, J R STAT SOC B, V34, P187
  • [7] MORBIDITY AND MORTALITY IN THE SWEDISH TRIAL IN OLD PATIENTS WITH HYPERTENSION (STOP-HYPERTENSION)
    DAHLOF, B
    LINDHOLM, LH
    HANSSON, L
    SCHERSTEN, B
    EKBOM, T
    WESTER, PO
    [J]. LANCET, 1991, 338 (8778) : 1281 - 1285
  • [8] LACUNAR STROKES AND INFARCTS - A REVIEW
    FISHER, CM
    [J]. NEUROLOGY, 1982, 32 (08) : 871 - 876
  • [9] THE STROKE DATA-BANK - DESIGN, METHODS, AND BASELINE CHARACTERISTICS
    FOULKES, MA
    WOLF, PA
    PRICE, TR
    MOHR, JP
    HIER, DB
    [J]. STROKE, 1988, 19 (05) : 547 - 554
  • [10] DECREASING INCIDENCE OF PRIMARY INTRA-CEREBRAL HEMORRHAGE - POPULATION STUDY
    FURLAN, AJ
    WHISNANT, JP
    ELVEBACK, LR
    [J]. ANNALS OF NEUROLOGY, 1979, 5 (04) : 367 - 373